92 related articles for article (PubMed ID: 34197747)
1. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Wei F
Lancet Oncol; 2021 Jul; 22(7):e284. PubMed ID: 34197747
[No Abstract] [Full Text] [Related]
2. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Pramanik R; Sharma A; Kumar A
Lancet Oncol; 2021 Jul; 22(7):e287. PubMed ID: 34197750
[No Abstract] [Full Text] [Related]
3. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Foo T; Kichenadasse G; Roy A; Karapetis CS
Lancet Oncol; 2021 Jul; 22(7):e286. PubMed ID: 34197749
[No Abstract] [Full Text] [Related]
4. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Brandi G; Frega G; Rizzo A
Lancet Oncol; 2021 Jul; 22(7):e285. PubMed ID: 34197748
[No Abstract] [Full Text] [Related]
5. Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.
Lamarca A; Palmer DH; Wasan HS; Ross PJ; Ma YT; Arora A; Falk S; Gillmore R; Wadsley J; Patel K; Anthoney A; Maraveyas A; Iveson T; Waters JS; Hobbs C; Barber S; Ryder WD; Ramage J; Davies LM; Bridgewater JA; Valle JW;
Lancet Oncol; 2021 Jul; 22(7):e288-e289. PubMed ID: 34197751
[No Abstract] [Full Text] [Related]
6. Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer-a commentary from the Young International Society of Geriatric Oncology.
Liposits G; Arora SP; Battisti NML; Soto-Perez-de-Celis E; Loh KP; Williams GR
Ann Oncol; 2023 Jun; 34(6):555-556. PubMed ID: 36813114
[No Abstract] [Full Text] [Related]
7. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
[TBL] [Abstract][Full Text] [Related]
8. Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care?
Rizzo A; Cusmai A; Palmiotti G
Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):201-203. PubMed ID: 35220859
[No Abstract] [Full Text] [Related]
9. Response to letter to the editor: Use, response and outcomes of second line chemotherapy in patients with advanced biliary tract cancers.
Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
J Oncol Pharm Pract; 2023 Jun; 29(4):1027. PubMed ID: 36972505
[No Abstract] [Full Text] [Related]
10. How we treat advanced biliary tract cancers in the second-line setting.
Ellis H; Raghavan S; Wolpin BM; Cleary JM
Clin Adv Hematol Oncol; 2023 Jan; 21(1):35-42. PubMed ID: 36638354
[No Abstract] [Full Text] [Related]
11. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
[TBL] [Abstract][Full Text] [Related]
12. First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4)
Schinzari G; Rossi E; Mambella G; Strippoli A; Cangiano R; Mutignani M; Basso M; Cassano A; Barone C
Anticancer Res; 2017 Sep; 37(9):5193-5197. PubMed ID: 28870954
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.
Kajanti M; Pyrhönen S
Am J Clin Oncol; 1994 Jun; 17(3):223-6. PubMed ID: 8192106
[TBL] [Abstract][Full Text] [Related]
14. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
15. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
16. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Ulusakarya A; Karaboué A; Ciacio O; Pittau G; Haydar M; Biondani P; Gumus Y; Chebib A; Almohamad W; Innominato PF
BMC Cancer; 2020 Jun; 20(1):515. PubMed ID: 32493242
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.
Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer; 2005 Jun; 103(11):2338-43. PubMed ID: 15825161
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer.
Eckel F; Lersch C; Assmann G; Schulte-Frohlinde E
Ann Oncol; 2000 Jun; 11(6):762-3. PubMed ID: 10942070
[No Abstract] [Full Text] [Related]
20. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
Mani S; Sciortino D; Samuels B; Arrietta R; Schilsky RL; Vokes EE; Benner S
Invest New Drugs; 1999; 17(1):97-101. PubMed ID: 10555128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
